Retrospective cohort study finds that thiamine supplementation reduces mortality in ICU patients with sepsis-associated delirium, suggesting beneficial implications.
Key Points
This research aims to evaluate the association between thiamine supplementation and 30-day mortality in ICU patients diagnosed with sepsis-associated delirium.
Conducted a retrospective cohort study using the MIMIC-IV database.
Included adult ICU patients meeting Sepsis-3 criteria diagnosed with delirium.
Categorized patients based on thiamine supplementation during ICU admission.
Employed propensity score methods for balancing baseline covariates.
Performed survival, subgroup, and sensitivity analyses, including duration–response and dose–response evaluations.
Thirty-day mortality was significantly lower in patients receiving thiamine (P < 0.001).
Thiamine use was associated with improved survival (HR, 0.51; 95% CI, 0.33–0.79; P = 0.002).
Consistent results across various propensity score analyses confirmed the survival benefit of thiamine supplementation.
Subgroup analyses indicated significant survival benefits for patients with SOFA scores < 4.
Duration-response and dose-response analyses suggested better outcomes with longer treatment duration and lower daily doses.